Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.51 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.51 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | PPARG | P37231 | 2/20 | 0.43 |
| ▸ | PPARA | Q07869 | 2/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | PRSS1 | P07477 | 4/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2204526 | 1.00 | CYP4F2 (0.51) | CYP4F2CYP4A11TAAR1KCNH2PPARG | |
| SCHEMBL2203546 | 0.95 | CYP4F2 (0.50) | CYP4F2CYP4A11TAAR1KCNH2PPARG | |
| SCHEMBL29818925 | 0.94 | CYP4F2 (0.49) | CYP4F2CYP4A11TAAR1KCNH2PPARG | |
| SCHEMBL2205041 | 0.94 | CYP4F2 (0.49) | CYP4F2CYP4A11TAAR1KCNH2PPARG | |
| SCHEMBL2206860 | 0.94 | CYP4F2 (0.51) | CYP4F2CYP4A11TAAR1KCNH2PPARG | |
| SCHEMBL610023 | 0.90 | CYP4F2 (0.51) | CYP4F2CYP4A11TAAR1KCNH2PPARG | |
| SCHEMBL2335254 | 0.89 | CYP4F2 (0.50) | CYP4F2CYP4A11TAAR1KCNH2PPARG | |
| SCHEMBL611426 | 0.89 | CYP4F2 (0.50) | CYP4F2CYP4A11TAAR1KCNH2PPARG | |
| SCHEMBL612944 | 0.88 | CYP4F2 (0.49) | CYP4F2CYP4A11TAAR1KCNH2PPARG | |
| SCHEMBL611425 | 0.88 | CYP4F2 (0.49) | CYP4F2CYP4A11TAAR1KCNH2PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12029708-B2 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2024-07-09 | — | — | US | disclosed |
| US-11446261-B2 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2022-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12029708-B2 | Alkoxy compounds for disease treatment | ALDH1A2, CLN6, AGER | CYP4F2 4298/4885CYP4A11 1129/4885TAAR1 1482/4885 |
| US-11446261-B2 | Alkoxy compounds for disease treatment | ALDH1A2, CLN6, AGER | CYP4F2 4298/4885CYP4A11 1129/4885TAAR1 1482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.